Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023418 (leukemia)
 93,477 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We have studied immunologic reactivity to leukemia-associated antigens in patients with chronic myelocytic leukemia (CML) treated with chemotherapy and adjunctive immunotherapy. All patients were immunologically competent as measured by skin test reactivity to dinitrochlorobenzene. Immunotherapy consisted of allogeneic irradiated leukemic myeloblasts injected intradermally, with BCG vaccine (Research Foundation, Chicago, Ill.) given by multiple puncture at the same site. 10(9) cells plus BCG were given weekly for 4 wk, and 10(8) cells plus BCG were given at monthly intervals thereafter. Eight patients judged clinically to be in the stable phase of their disease developed circulating antibody against the immunizing blast cells demonstrable by cytotoxicity and immunofluorescence assays. The antibody also showed reactivity against a panel of myeloblasts (12 paients) but not against the corresponding remission lymphocytes (five patients) or normal lymphocytes (20 donors). In two cases the antibody showed reactivity against the patient's own leukemic blasts. Seven of these eight patients have maintained a steady clinical course ranging from 20 to 40 mo, while one entered the blastic phase and died. Six patients were judged to be in the aggressive phase of CML because of progressive leukocytosis and splenomegaly or increasing myeloblastosis; five died an average of 16 mo after diagnosis. Humoral antibodies were not detected in these patients after repeated courses of BCG and allogeneic leukemic cells. We conclude that specific active immunotherapy of patients with CML can abet the production of humoral antibody against blast cell antigens and that this response may be impaired during the aggressive phase of the disease.
 ...
PMID:Antibody responses to leukemia-associated antigens during immunotherapy of chronic myelocytic leukemia. 106 Apr 71

Thirteen patients with acute myeloblastic leukaemia or one of its variants in remission have been given maintenance treatment with a combination of chemotherapy and immunotherapy. Chemotherapy was given for one week in four, and immunotherapy was given during the intervening three weeks. The immunotherapy consisted of BCG vaccine given by Heaf gun, and snap-frozen pooled allogeneic irradiated leukaemic cells. The median duration of survival was 147 weeks, and the median duration of the first complete remission was 76 weeks. It is difficult to compare these results with other figures reported, but they add to the evidence which suggests that immunotherapy is of value in the maintenance treatment of patients with this disease. Further controlled trials are necessary.
 ...
PMID:Immunotherapy with chemotherapy in the maintenance of remission in acute myeloblastic leukaemia. 106 38

Experiments on 150 non-inbred white rats have shown that preliminary administration of high polymer native DNA isolated from Swetz leukemia tumor suppresses the tumor growth. Tumor DNA combined with BCG vaccine in young animals suppresses and in old ones stimulates the tumor growth. These results correlate with DNA and CIC content in the blood serum. Due to the tumor growth suppression the animals' life increases by 40%. Administration of BCG vaccine only does not prevent the development of tumor in usual terms.
 ...
PMID:[Effect of exogenous neoplasm DNA on the course of Swetz leukemia in non-inbred rats of different age groups]. 176 92

In total, 28 deaths from leukaemia are known to have occurred among the 54,239 participants in the Medical Research Council tuberculosis vaccines trial (initially aged about 14 years), from its beginning in 1950 to the end of 1979. There is evidence that this total is likely to be very nearly complete. During the entire period (average 27.1 years) the leukaemia mortality per million person-years was 25 in the BCG vaccinated group, 20 in the vole-bacillus vaccinated group, and 21 in the randomly-allocated unvaccinated (control) group. Although there was neither a benefit nor a disadvantage from vaccination over the whole period, detailed figures suggested that there may have been a beneficial effect against leukaemia during the first 15 years after entry (that is between age 15 and 30 years) and a deleterious effect after longer intervals (or above the age of 30 years). Alternatively this swing may simply represent an unusual chance fluctuation. There has been no sign in recent years of any substantial decrease in leukaemia mortality in England and Wales at ages 15-29 years, although the proportion of children given BCG vaccine at about age 13 years has risen from less than 1 per cent (for the cohort aged 15-19 years in 1951-1955) to more than 70 per cent 25 years later. It has therefore been provisionally concluded that chance is the explanation for the apparent swing from prevention to enhancement, and that BCG vaccination at age 13-14 years in Great Britain does not affect subsequent mortality from leukaemia.
 ...
PMID:BCG and vole bacillus vaccination in adolescence and mortality from leukaemia. 676 27

A previous report of nosocomial infection due to Mycobacterium bovis bacille Calmette-Guerin (BCG) implicated contamination of chemotherapy solutions reconstituted under the same biosafety hood as BCG vaccine used for bladder cancer therapy. We report 3 similar BCG infections in children and describe evidence of respiratory transmission to health care workers (HCWs) from 1 patient. These children were receiving chemotherapy for leukemia when they presented with active tuberculosis. Each isolate was identified biochemically and by both gas-liquid chromatography and major polymorphic tandem repeat-polymerase chain reaction. Pulsed-field gel electrophoresis showed that 2 isolates were identical strains and identical to the Tice and Connaught strains licensed in the United States for bladder chemotherapy. The third isolate differed by a single fragment after DraI restriction. One patient with heavily positive sputum exposed numerous HCWs. Of 41 HCWs, 2 (5%) converted their purified protein derivatives (PPD) skin test. These data underscore the risk of nosocomial BCG transmission by contamination of chemotherapy solutions and demonstrate the potential for transmission to HCWs from patients with active pulmonary disease.
 ...
PMID:Nosocomial transmission of Mycobacterium bovis bacille Calmette-Guerin to children receiving cancer therapy and to their health care providers. 1067 41